Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLORY: Glofitamab-based Therapy for DLBCL in Older Adults
NCT06765317Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2025
- Primary completion
- Jan 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), transformed lymphoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Jan 2025; status: recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)transformed lymphoma
Beyond the preview
Go deeper on NCT06765317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06765317.